Federal Agency · U.S. National Science Foundation
Engineering Biological and Biomedical Systems (EBBS)
Last updated: October 23, 2026
Posted April 24, 2026
Funding
Funding amount not specified
Closes
Rolling
NAICS
541715
The Engineering Biological and Biomedical Systems (EBBS) program expands our understanding of biological and physiological systems, and it helps improve human health. For U.S. leadership in biotechnology, the engineering of biology is required at every scale. Engineering is needed for sensing biomarkers to making proteins to restoring functions of the body. In EBBS, fundamental mechanistic insights are combined with experimental and computational techniques. This approach helps develop platforms, devices, organisms, tissues, and processes that bring new understanding and control of biological functions. EBBS supports studies of mechanisms that drive the behavior of microbial populations and cells, and of therapeutic cells and tissues. This includes discovering the underlying engineering principles that are needed to capture the responses of biological systems and bioreactors. It also includes the creation of novel biosensing platforms and new optical imaging and modulation strategies. Research that enables the design of biological systems to sense and respond to novel stimuli is welcome. Similarly, projects leading to insight into tissue changes or injury, and to systems that imitate or restore the functions of tissues or organs are encouraged. Projects that advance rehabilitation engineering through new theories and approaches are supported by the EBBS program. Fundamental engineering research driven by the needs of persons with disabilities is encouraged. The EBBS program expands what is possible in biomanufacturing; research may advance biotechnology and/or health. EBBS research must enable improved biological processes, create novel biomedical technologies, or achieve new understanding of physiological or pathological processes. EBBS does not support proposals with a main goal of drug design, drug delivery, or the development of animal models of disease. Using existing models for experimental testing and validation is acceptable. Projects that focus on testing and validating therapies are not supported. Clinical trials are not supported. Limited studies involving human volunteers may be supported if appropriate to the project objectives. Projects focused on commercialization are more appropriate for the NSF Directorate for Technology, Innovation, and Partnerships (TIP). Partnerships: To speed discovery and innovation, NSF partners with federal agencies, industry, international groups, and others. Current opportunities are at NSF ENG Partnerships.
Eligibility
- Funded by NSF
- Programs related to manufacturing
- Programs related to biotechnology
Categories
Research Innovation
Sign up at GrantRegister to see if this grant matches your organization.
Match my organization →View application on Grants.gov →·Source: Grants.gov·Last seen Oct 23, 2026
Similar grants
- Emergency Medical Services Technical Assistance (EMS TA) Solicitation for Proposals (SFP) for Program Year 2026 (PY 26-27)Employment Development Department · closes October 27, 2026
- GREGoRi Innovation Projects (U01 Clinical Trial Optional)National Institutes of Health · closes October 30, 2026
- Emergency Medical Services (EMS) Grant for Program Year 2026-27 (PY 26-27)Employment Development Department · closes November 2, 2026
- NSF Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs: A Pilot Emphasis on Scientific InstrumentationU.S. National Science Foundation · closes November 4, 2026
- 1890 Institution Teaching, Research, and Extension Capacity Building Grants ProgramNational Institute of Food and Agriculture · closes November 4, 2026
- Unlocking Dataset Value for AI-Enabled Scientific Discovery (AI Datasets)U.S. National Science Foundation · closes November 4, 2026
- CLEAN AND SAFE WATEREnvironmental Protection Agency · closes November 8, 2026
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)National Institutes of Health · closes November 13, 2026
